Skip to Content

Strensiq Approval History

  • FDA approved: Yes (First approved October 23rd, 2015)
  • Brand name: Strensiq
  • Generic name: asfotase alfa
  • Dosage form: Injection
  • Company: Alexion Pharmaceuticals, Inc.
  • Treatment for: Hypophosphatasia

Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal, infantile and juvenile-onset hypophosphatasia (HPP).

Development History and FDA Approval Process for Strensiq

Oct 23, 2015Approval FDA Approves Strensiq (asfotase alfa) for Perinatal, Infantile and Juvenile-Onset Hypophosphatasia
Dec 30, 2014Alexion Completes Rolling BLA Submission to FDA for Asfotase Alfa for Hypophosphatasia
Mar 29, 2012Asfotase Alfa Significantly Decreased TNSALP Substrates and Improved 6-Minute Walk Test Results in Adolescents and Adults with Hypophosphatasia (HPP)
Mar  7, 2012New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.